重组细胞因子基因衍生蛋白与干扰素α-2b分别联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者疗效研究*

doi:10.3969/j.issn.1672-5069.2023.01.008

摘要/Abstract

摘要： 目的观察比较应用重组细胞因子基因衍生蛋白或干扰素α-2b分别联合恩替卡韦治疗血清HBeAg阳性的慢性乙型肝炎(CHB)患者的疗效。方法 2019年3月～2021年3月我院诊治的65例血清HBeAg阳性的CHB患者被分成两组,分别给予干扰素α-2b联合恩替卡韦治疗或重组细胞因子基因衍生蛋白联合恩替卡韦治疗48 w。常规检测血清生化学、血清学和病毒学指标。结果在治疗12 w末,恩替卡韦联合重组细胞因子基因衍生蛋白治疗组血清HBeAg转阴率和HBeAg血清转换率分别为34.4%和25.0%,均显著高于恩替卡韦联合干扰素α-2b治疗组的9.1%和6.1%,差异有统计学意义(P<0.05);在治疗48 w末,恩替卡韦联合重组细胞因子基因衍生蛋白治疗组血清ALT复常率、血清HBeAg转阴率和HBeAg血清转换率分别为87.5%、62.5%和40.6%,均显著高于恩替卡韦联合干扰素α-2b治疗组的78.8%、30.3%和18.2%,差异有统计学意义(P<0.05);在治疗期间,联合干扰素治疗组乏力和发热头痛发生率分别为21.2%和84.9%,显著高于联合衍生蛋白治疗组的3.1%和3.1%(P＜0.05),而两组中性粒细胞减少、血小板减少、食欲下降和低钙血症等不良反应发生率比较差异无统计学意义(P＞0.05)。结论相比于干扰素α-2b联合恩替卡韦,应用重组细胞因子基因衍生蛋白联合恩替卡韦治疗血清HBeAg阳性的CHB患者能够获得更好的血清学转换率和较小的不良反应,值得进一步观察研究。

关键词: 慢性乙型肝炎, HBeAg阳性, 重组细胞因子基因衍生蛋白, 干扰素α-2b, 恩替卡韦, 治疗

Abstract: Objective The aim of this study was to compare the antiviral efficacy of recombinant cytokine gene-derived protein (RCGDP) or human interferon α-2b and entecavir combination in the treatment of patients with serum HBeAg positive chronic hepatitis B (CHB). Methods 65 patients with serum HBeAg-positive CHB were recruited in our hospital between March 2019 and March 2021, and were divided into two groups. The interferon α-2b and entecavir combination were given in 33 patients and the RCGDP and entecavir combination were given in 32 patients with CHB. The regimen lasted for 48 weeks in both groups. Serum alanine aminotransferase (ALT) levels, HBV DNA loads and serum HBeAg seroconversion were recorded. Results At the end of 12 week treatment, serum HBeAg negative and HBeAg seroconversion rates in patients receiving entecavir and RCGDP combination were 34.4% and 25.0%, both significantly higher than 9.1% and 6.1% in patients receiving entecavir and interferon α-2b combination therapy (P<0.05); at the end of 48 week treatment, serum ALT normalization, serum HBeAg negative and HBeAg seroconversion rates in patients receiving entecavir and RCGDP combination were 87.5%, 62.5% and 40.6%, all significantly higher than 78.8%, 30.3% and 18.2% in patients receiving entecavir and interferon α-2b combination therapy (P<0.05); during the treatment period, the incidences of fatigue, and fever and headache in entecavir and interferon α-2b combination-treated patients were 21.2% and 84.9%, both significantly higher than 3.1% and 3.1%(P＜0.05)in entecavir and RCGDP combination–treated patients, while there were no significant differences as respect to the incidences of neutropenia, thrombocytopenia, decreased appetite, and hypocalcemia between the two groups (P>0.05) . Conclusion The administration of recombinant cytokine gene-derived protein and oral entecavir combination is efficacious in treatment of patients with serum HBeAg positive CHB, with a high HBeAg seroconversion and less untoward effects, as compared with interferon α-2b and entecavir combination therapy, which needs further multi-central clinical investigation.

Key words: Hepatitis B, HBeAg positive, Recombinant cytokine gene-derived protein, Human interferon α-2b, Entecavir, Therapy

张丹, 江建新. 重组细胞因子基因衍生蛋白与干扰素α-2b分别联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 27-30.

Zhang Dan, Jiang Jianxin. Comparison of response to recombinant cytokine gene-derived protein or human interferon α-2b and entecavir combination in the treatment of patients with serum HBeAg positive chronic hepatitis B[J]. Journal of Practical Hepatology, 2023, 26(1): 27-30.

参考文献

[1] Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis, 2016, 16( 6) : 712-723.
[2] Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet, 2014, 384(9959) : 2053-2063.
[3] Van Damme P. Long-term protection after hepatitis B vaccine.J Infect Dis, 2016,214( 1) : 1-3.
[4] Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet,2015,386( 10003) : 1546-1555.
[5] Choi WM, Choi J, Lim YS. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis.Clin Gastroenterol Hepatol, 2021,19(2):246-258.
[6] Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2020,5(12):1039-1052.
[7] Lewczuk N, Zdebik A, Bogusławska J. Interferon alpha 2a and 2b in ophthalmology: a review. J Interf Cytok Res, 2019, 39(5):259-272.
[8] Jiong Y, Xuan L, Ling T, et al. Interferon-α-2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease-2019. Br J Clin Pharmacol, 2021, 87(12):4737-4746.
[9] 梁超,毛重山,闫宏宪. 重组人干扰素α-2b联合恩替卡韦对慢性乙型肝炎患者免疫功能的影响. 药物评价研究,2019,42(5):967-969.
[10] 汪玲,龚国忠,孙克伟,等. 重组细胞因子基因衍生蛋白注射液(乐复能)治疗HBeAg阳性CHB的疗效和安全性. 中华临床感染病杂志,2020,13(4):276-281.
[11] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[12] Basch E, Becker C, Rogak LJ, et al.Composite grading algorithm for the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).Clin Trials, 2021,18(1):104-114.
[13] Jindal A, Kumar M.Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues. Hepatol Int, 2021,15(1):1-3.
[14] Mak LY, Cloherty G, Wong DK, et al.HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy.Hepatology,2021,73(6):2167-2179.
[15] Rashed Ul, Islam SM, Shahera U,et al. Prevalent HBeAg-negative HBV DNA-positive chronic hepatitis B individuals in Bangladesh. Euroasian J Hepatogastroenterol, 2021,11(1):49-50.
[16] Lin S, Fu Y, Wu W, et al.The efficacy of addition of tenofovir fisoproxil fumarate to peg-IFNα-2b is superior to the addition of entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of peg-IFNα-2b treatment alone.Int J Med Sci,2020,17(10):1458-1463.
[17] 黄登,潘智,谢林钦,等. 重组人干扰素α-2b联合恩替卡韦对HBeAg阳性乙肝患者病毒转阴及免疫功能的影响. 浙江医学,2020,42(12):1299-1302.
[18] 赵鸿,斯崇文,魏来,等. 聚乙二醇化干扰素α-2b与干扰素α-2b治疗e抗原阳性CHB的疗效和安全性的随机对照多中心研究. 中华肝脏病杂志,2006,14(5):323-326.
[19] Xing L W, Rui Y D, Zeng Q Y.The interferon antagonistic activities of the V proteins of NDV correlated with their virulence.Virus Genes, 2019,55(2):233-237.
[20] Liu J, Liang WN, Jing WZ, et al. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Heal Organ, 2019,97(3): 230-238.
[21] Trépo C, Chan HL, Lok A.Trépo C, et al. Hepatitis B virus infection. Lancet, 2014,384(9959):2053-2063.
[22] Wilkins T, Sams R, Carpenter M, et al. Hepatitis B: Screening, prevention, diagnosis, and treatment. Am Fam Physician, 2019,99(5):314-323.
[23] Zampino R, Boemio A, Sagnelli C, et al. Hepatitis B virus burden in developing countries. World J Gastroenterol,2015,21(42):11941-11953.
[24] Hedley-Whyte J, Milamed DR, Hedley-Whyte J, et al. Hepatitis B: Prevalence, hope. Ulster Med J, 2019, 88(2):118-123.

重组细胞因子基因衍生蛋白与干扰素α-2b分别联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*

Comparison of response to recombinant cytokine gene-derived protein or human interferon α-2b and entecavir combination in the treatment of patients with serum HBeAg positive chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄晓铨, 陈世耀. 重视规范化处理门静脉高压并发食管胃静脉曲张出血^*[J]. 实用肝脏病杂志, 2023, 26(1): 1-3.
[2]	申艳, 陈琳. 内镜治疗食管胃静脉曲张破裂出血及其长期管理^*[J]. 实用肝脏病杂志, 2023, 26(1): 8-10.
[3]	李苏苏, 董媛, 贾浩延, 秦颖. 门冬氨酸鸟氨酸联合结肠透析治疗肝性脑病患者疗效及其对血浆β-EP和LPS的影响^*[J]. 实用肝脏病杂志, 2023, 26(1): 75-78.
[4]	戴欢, 李凯, 朱永湘, 王超. 内镜下套扎和注射硬化剂治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 87-90.
[5]	丁海斌, 张欣, 李雅, 聂磊, 常柏玲, 王颖栋. TACE序贯微波消融联合索拉非尼治疗大肝细胞癌患者临床疗效研究[J]. 实用肝脏病杂志, 2023, 26(1): 108-111.
[6]	彭雨, 李海涛, 杨文丽, 余意. PD-1抑制剂联合仑伐替尼治疗老年中晚期原发性肝癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 112-115.
[7]	东贤进, 苏伟, 李连生, 谢智, 高军林. 腹腔镜肝切除术与开腹肝切除术治疗肝内胆管细胞癌患者短期临床疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 120-123.
[8]	尹秋实, 王学国, 宋奇锋. 腹腔镜肝切除术治疗肝内胆管结石病患者临床疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 124-127.
[9]	张福, 陈俊卯, 梁晓辉. LCBDE术一期缝合治疗胆总管结石患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 128-131.
[10]	刘颂航, 高友逵, 曹良启. LC联合ERCP治疗胆囊结石合并肝外胆管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 132-135.
[11]	贾春锋, 高旋, 徐倩, 刘建华. 不同HBsAg水平的慢性乙型肝炎患者血清HIF-1α、ApoE和TGF-β1水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2023, 26(1): 140-141.
[12]	张子侠, 李德林, 张国梁. RFA联合益脾养肝方治疗原发性肝癌患者临床疗效观察[J]. 实用肝脏病杂志, 2023, 26(1): 142-144.
[13]	韩芳, 李佳峥, 南月敏. 肝硬化并发急性肾损伤诊治进展[J]. 实用肝脏病杂志, 2022, 25(6): 768-771.
[14]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[15]	吴凤萍, 崔丹丹, 王怡恺, 李梅, 刘晨瑞, 南希, 贾晓黎, 党双锁. 血清BAFF预测聚乙二醇干扰素-α治疗非活动性HBsAg携带者临床治愈的效能分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 780-783.